DexCom Stock Got Crushed After an Earnings Miss. A New Product Could Bail It Out. -- Barrons.com
Morgan Stanley Maintains DexCom(DXCM.US) With Hold Rating, Cuts Target Price to $75
Dexcom Announces Upcoming Conference Presentation
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $38,000 Today
Self-Monitoring Blood Glucose Device Market Report and Company Analysis 2024-2032 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, Novo Nordisk - ResearchAndMarkets.com
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $89
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch
Healthy Returns: What to Know About the Latest Round of Pfizer, Moderna Covid Vaccines
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $80 to $120
Dexcom's Stelo CGM Launch Promises Substantial Market Penetration and Revenue Growth: A Strong Buy Recommendation
Barclays Keeps Their Hold Rating on Dexcom (DXCM)
Jim Cramer Says 'One of the Most Dramatic Declines Of This Year Comes From DexCom Inc. (DXCM)'
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
Reported Earlier, Dexcom Announces Stelo, The First Over-The-Counter Glucose Biosensor In The U.S., Is Now Available For Purchase Without A Prescription
Dexcom Launches First Over-the-counter Continuous Glucose Monitor. Here's What It's Like
At US$74.07, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?
Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available
Is Wall Street Bullish or Bearish on DexCom Stock?
Stifel Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100